相关实验视频

Updated: Jul 5, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

在患有复发性形性寡质瘤的患者中成功消毒,呈现出与普卡巴因介导的过敏反应相关的症状

Hazal Kayikçi¹, Özge Can Bostan², Gülseren Tuncay¹

¹Faculty of Medicine, Division of Allergy and Clinical Immunology, Hacettepe University Hospital, Ankara, Turkey.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

|January 23, 2024

概括

超敏反应是一种罕见的过敏反应,可以通过脱敏方案来管理,使患者能够继续进行关键的化疗. 这个案例证实了协议.

科学领域:

在瘤学瘤学.
临床药理学临床药理学

背景情况:

普罗卡巴是治疗大脑恶性瘤的口服化疗剂.
过敏反应,包括过敏反应,是已知的普拉卡巴辛的不良影响.
4级反应的标准管理包括避免重新挑战,除非有治愈作用,否则可以考虑降低敏感性.

研究的目的:

报告一个成功的病例的无敏化在一个患有 procarbazine 诱导的过敏反应的病人.
评估在严重过敏反应后继续使用普卡巴辛化疗的可行性.

主要方法:

一名患有复发性阿纳普拉斯 oligodendroglioblastoma 的患者在进行 procarbazine 治疗时出现过敏反应.
进行了12个步骤的脱敏方案,包括前期治疗.
患者在脱敏后成功完成了化疗周期.

主要成果:

在患有严重过敏反应的患者中,成功地实现了对前素的脱敏.
患者能够继续接受普拉卡巴辛化疗,完成治疗周期.
这个案例支持使用procarbazine脱敏方案.

结论:

普罗卡巴氨酸过敏症很少见,但可以通过无敏化来管理.
据报道,无敏化方案使大脑恶性瘤的持续化疗成为可能.
需要进一步的病例报告来证实procarbazine脱敏的有效性和适用性.

关键词:

过敏反应 (ANAPHYLAXIS) 是一种过敏反应.过敏性性寡聚质质瘤对于前卡巴的脱敏化疗法

更多相关视频

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

相关概念视频

Desensitization and Tachyphylaxis

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

GPCR Desensitization

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Allergic Reactions

Allergic Reactions